Clinical Trials Updates: AMG 509 and Lorikeet

Dr. Crawford outlined the LORIKEET study and the AMG509 clinical trial. To conclude the webinar, the audience answered several poll questions. In total, 96% of the attendees were satisfied with the meeting and presentations, and 88% rated the speakers as ‘very good.’ Also, 83% now understand how the PSMA PET scan can help track and manage prostate cancer treatment. Most importantly, 97% of attendees understand the value of continual PSA screening to manage survivorship.